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Abstract
A balanced pool of hematopoietic stem cells (HSCs) in bone marrow is tightly regulated, and this regulation is disturbed in
hematopoietic malignancies such as chronic myeloid leukemia (CML). The underlying mechanisms are largely unknown.
Here we show that the Lin
2Sca-1
+c-Kit
- (LSK
2) cell population derived from HSC-containing Lin
2Sca-1
+c-Kit
+ (LSK) cells has
significantly higher numbers of apoptotic cells. Depletion of LSK cells by radiation or the cytotoxic chemical 5-fluorouracil
results in an expansion of the LSK
2 population. In contrast, the LSK
2 population is reduced in CML mice, and depletion of
leukemia stem cells (LSCs; BCR-ABL-expressing HSCs) by deleting Alox5 or by inhibiting heat shock protein 90 causes an
increase in this LSK
2 population. The transition of LSK to LSK
2 cells is controlled by the Icsbp gene and its downstream gene
Lyn, and regulation of this cellular transition is critical for the survival of normal LSK cells and LSCs. These results indicate a
potential function of the LSK
2 cells in the regulation of LSK cells and LSCs.
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Introduction
Hematopoietic stem cells (HSCs) are contained in the LSK cell
population are responsible for producing variable types of mature
blood cell lineages. However, little is known about whether and
how LSK cells are functionally regulated by other cell lineages that
are derived from LSK cells and express similar cell surface
markers. Phenotypically, LSK cells express Sca-1 and c-Kit, but
lack the lineage (Lin) markers expressed on mature myeloid and
lymphoid cells [1,2,3,4]. The HSC-containing Lin
2Sca-1
+c-Kit
+
(LSK) cell population is capable of self-renewing and differenti-
ating into a c-Kit-negative population (Lin
2Sca-1
+c-Kit
2, LSK
2)
that lacks the ability to reconstitute lethally irradiated mice [5],
indicating that LSK
2 cells do not have long-term stem cell
reconstitution capability. Paradoxically, this cell population is
shown to contain distinctive lymphoid progenitor cells [6],
suggesting that LSK
2 cells have some stem cell-like functions.
This cell population also appears to be related to the development
of a hematologic malignancy derived from leukemia stem cells
(LSCs). For example, in mice with BCR-ABL induced chronic
myeloid leukemia (CML), BCR-ABL-expressing LSK cells func-
tion as LSCs [7], and besides BCR-ABL-expressing LSK cells, the
bone marrow of CML mice also contains BCR-ABL-expressing
LSK
2 cells [8,9], although transplantation of cells containing the
LSK
2 cell population does not induce CML in secondary
recipient [7]. Together, these results prompted us to hypothesize
that although LSK
2 cells do not function as HSC-containing LSK
cells or LSCs, they play a critical role in regulating the survival of
these stem cells in both normal and malignant situations through
unknown mechanisms. Proper regulation of the LSK population is
crucial for normal blood development [10,11,12]. In CML,
improper regulation of LSCs occurs, resulting in an increase in the
LSC population [8,13]. It will be important to study the regulatory
mechanisms responsible for survival and maintenance of normal
LSK cells and LSCs. In this study, we demonstrate that LSK cells
and LSCs in CML regulate their survival through becoming a
more apoptotic cell population and that this cellular transition is
controlled by the Icsbp gene and its downstream gene Lyn.
Results
LSK derived LSK
2 cell population is related to survival
regulation of LSK cells
Because LSK
2 cells are derived from LSK cells and lack the
ability to reconstitute lethally irradiated mice [5], we reasoned that
this cell population is incapable of giving rise to LSK cells,
progenitor cells and more mature cell lineages. To provide more
supporting evidence, we transferred 1610
4 LSK
2 cells or 1610
3
LSK cells (as a positive control) from CD45.1 C57BL/6J (B6) mice
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the bone marrow transplantation, FACS analysis showed that
donor-derived CD45.1 LSK and LSK
2 cells were detected in
bone marrow of recipients of CD45.1 LSK cells as expected, but
neither cell population was detected in bone marrow of recipients
of CD45.1 LSK
2 cells (Fig. 1A). In addition, no donor-derived
mature myeloid (Gr1
+CD45.1
+ and Mac1
+CD45.1
+) and B-
lymphoid cells (B220
+CD45.1
+) were detected in peripheral blood
of recipients of CD45.1 LSK
2 cells (Fig. 1A). These results
indicate that the LSK
2 cell population lacks long-term stem cell
reconstitution function or an ability to give rise to LSK cells,
consistent with the failure of LSK
2 cells to reconstitute lethally
irradiated mice [5]. Although LSK cells give rise to LSK
2 cells, we
wanted to know whether the LSK
2 cells could be directly
differentiated from LSK or from other lineage negative popula-
tions. First, we sorted LSK cells from bone marrow of B6 mice,
and treated the cells with the cytotoxic agent 5-FU or irradiation in
vitro. The cells were then cultured for examining whether LSK
2
population could be produced directly from LSK cells. After the
treatment with irradiation or 5-FU, we detected higher percent-
ages of LSK
2 cells compared to the untreated control (Figure 1B).
Second, we similarly treated Lin
2Sca-1
-c-Kit
+ (LS
2K; represent-
ing progenitor cells) with 5-FU or irradiation, and barely detected
any LSK
2 cells (Fig. 1B), indicating that LS
2K cells do not give
rise to LSK
2 cells. Finally, we tested whether LSK
2 cell could
arise from Lin
2Sca-1
-c-Kit
2 (LS
2K
2) cells by carrying out an in
vivo reconstitution experiment. We transplanted 1610
6 CD45.1
LS
2K
2 cells into each CD45.2 recipient mouse, and continuously
monitored CD45.1 donor cells in the recipient mice at 1, 2, 4, 8
and 16 weeks post bone marrow transplantation (BMT). At the
first week, small percentages of CD45.1 cells were detected
(Fig. S1A), but with time, CD45.1 cells disappeared in CD45.2
recipient mice (Fig. S1A, S1B), indicating that LS
2K
2 cells do not
give rise to any other populations including LSK
2 cells.
It is possible that the transition of LSK cells to LSK
2 cells
provides a cellular mechanism for regulating the LSK population.
To test this idea, we compared apoptotic rates of three LSK
derived cell populations in bone marrow: LSK, LSK
2 and LS
2K.
By FACS analysis of Annexin V
+/7-AAD
+ cells, we observed that
apoptotic rates of LSK and LS
2K cells were low (0.9% and 0.6%
in average, respectively), but apoptotic rate of LSK
2 cells was
much higher (7.2% in average) (Fig. 1C). We also compared the
percentages of dividing cells in these three LSK derived cell
populations in bone marrow, and found that the percentage of
LSK
2 cells in the S+G2M phase was much lower than those in the
other two populations (Fig. 1D). These results indicate that the
LSK
2 population represents a pool of resting and apoptotic cells.
Because LSK
2 cells are derived from LSK cells [5] and
incapable of giving rise to LSK cells (Fig. 1A), it is possible that
LSK
2 cells regulates LSK cells through providing an apoptotic
cellular pathway to regulate the pool size of the LSK population
through controlling the degree of the transition of LSK cells to
more apoptotic LSK
2 cells. To test this hypothesis, we examined
whether induction of apoptosis of LSK cells is associated with an
increase in the LSK
2 population in vivo. First, we lethally
irradiated B6 mice, and found that the irradiation induced
apoptosis of LSK cells in bone marrow (Fig. 2A), which
accompanied with a decrease of LSK cells and an increase of
LSK
2 cells (Fig. 2B). Second, we treated B6 mice with 5-FU,
which has been shown to reduce LSK cells within initial two days
of the treatment [14], and found that apoptosis of LSK cells also
accompanied with a decrease of LSK cells and an increase of
LSK
2 cells (Fig. 2C, D).
An increase in LSK
2CD150
- cells reflects apoptosis of LSK
cells
CD150 is a major SLAM family receptor expressed on HSCs
and has been shown to be a useful cell surface marker for
classifying LSK cells into a highly enriched stem cell population
[15]. To more clearly show the relationship between the apoptotic
LSK
2 cell population and HSCs, we further narrowed down the
LSK and LSK
2 populations by adding CD150 analysis, and re-
validated our 5-FU and irradiation experiments shown in Fig. 2.
We found that in normal B6 mice, about 1/4 (23.2%) of bone
marrow LSK cells in the lineage-negative (Lin
2) population were
CD150 positive and 3/4 (76.8%) of these cells were CD150
negative (Fig. 3A); both cell populations had similar apoptotic rates
(3.4% and 3.5%; Fig. 3B). In contrast, greater than 90% the LSK
2
cells were CD150
2, with only about 5.4% of CD150
+ cells; both
populations also had similar apoptotic rates (13% and 14%;
Fig. 3B), which were much higher than those for the LSK cells.
Thus, the addition of CD150 staining to LSK
+ and LSK
2 cells
gave the same result as the one obtained without using the CD150
marker (Fig. 2A, D). In addition, because almost all cells in the
LSK
2 population are CD150
2 (Fig. 3A), the addition of CD150
staining would not change the result for the apoptotic rate of this
cell population. To further emphasize this point, we repeated our
5-FU and irradiation experiments (Fig. 2) by adding the CD150
staining to LSK
+ and LSK
2 cells. Comparing to untreated mice
(Day 0) in which LSK
2 cells were basically negative for CD150
(about 95% of LSK
2 cells were CD150
2), both treatments caused
a remarkable increase in the LSK
2CD150
2 population as
expected and also surprisingly in the LSK
2CD150
+ population,
suggesting that a significant number of HSCs (LSK
+CD150
+)
made a quick transition after irradiation or 5-FU treatment to
become apoptotic LSK
2 cells, presumably without having time to
turn down CD150 expression. In contrast, in a normal situation
there are few LSK
2CD150
+ cells (Fig. 3A). The increase of the
LSK
2CD150
2 population after irradiation or 5-FU treatment
accompanied with the decrease of the LSK
+CD150
+ population.
This result, in addition to the fact that LSK
2 cells are basically
negative for CD150, demonstrates that an increase in the LSK
2
population detected without using the CD150 marker should
accurately reflect cellular transition of HSCs and LSCs to the
LSK
2 population and apoptosis of these stem cells. Therefore, we
excluded the use of the CD150 marker in the rest of our
experiments in this study.
The LSK
2 cell population is associated with apoptosis of
LSCs
If LSK
2 cell population represents an apoptotic regulatory
pathway for LSK cells, in a hematologic malignancy the transition
of malignant LSK cells to apoptotic LSK
2 cells could be blocked.
To test this possibility, we first intended to show that in CML
mice, leukemia stem cells (LSC; BCR-ABL
+ LSK cells) also
undergo transition to BCR-ABL
+LSK
2 cells. Because only BCR-
ABL
+LSK cells are capable of self-renewing and initiating
leukemia in secondary recipient mice, transferring LSC-containing
bone marrow cells in CML mice to secondary recipient mice
allows examination of the transition of BCR-ABL
+LSK to BCR-
ABL
+LSK
2 cells. To induce primary CML, we transduced bone
marrow cells from wild type (WT) B6 mice with BCR-ABL-GFP
retrovirus (GFP serves as an indicator for BCR-ABL expression),
followed by transplantation of the transduced cells into lethally
irradiated B6 recipient mice [9,16]. Next, we transplanted 1610
6
total bone marrow cells from primary CML mice to each
secondary recipient mouse, and the mice developed CML and
Apoptosis of Normal and Leukemic Stem Cells
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38614died of CML within 4 weeks (Fig. S2A, S2B). After 15 days of
secondary transplantation, we analyzed the GFP
+LSK and LSK
2
populations in bone marrow of the secondary CML mice, and
detected by FACS both BCR-ABL
+LSK and LSK
2 cells,
demonstrating that the LSK to LSK
2 transition also occurs for
LSCs (Fig. 4A). This finding allowed us to further study the role of
LSK
2 cells in regulation of LSCs. We first examined whether the
percentage of bone marrow LSK
2 cells is decreased in mice with
BCR-ABL induced CML. We found that the average percentage
of GFP
+LSK
2 cells in CML mice at 20 days after the disease
induction was significantly lower (2.7%; Fig. 4B) than that of
GFP
-LSK
2 cells (7.4% in average; data not shown) and that of
LSK
2 cells in normal B6 mice (8.9%; Fig. 2B). To provide more
evidence supporting the role of GFP
+LSK
2 cells in regulating
apoptosis of LSCs in CML, we induced CML using the BCR-ABL
transduced bone marrow cells from mice lacking the Alox5 gene
(Alox5
2/2), as in the absence of Alox5, BCR-ABL fails to induce
CML due to a functional defect in Alox5
2/2 LSCs [17]. We
compared the number of GFP
+LSK
2 cells in bone marrow of
mice receiving BCR-ABL transduced Alox5
2/2 donor bone
Figure 1. The LSK
2 cell population is derived from LSK cells and provides an apoptotic cellular pathway for LSK cells. (A) LSK
(Lin
2Sca1
+c-Kit
+) cells (1610
3) and LSK
2 (Lin
2Sca1
+c-Kit
2) cells (1610
4) were sorted from bone marrow cells of CD45.1
+ wild type (WT) mice by FACS,
and transferred into lethal irradiated CD45.2
+ WT recipient mice. 12 weeks later, bone marrow cells were collected and stained with antibodies for
CD45.1, lineage markers, Sca21 and c-Kit. Peripheral blood cells were also collected and stained with antibodies for CD45.1, Gr-1, Mac21 and B220.
(B) LSK cells were sorted from bone marrow of C56BL/6 (B6) mice by FACS and were irradiated (2000 cGy, once) or treated with 5-FU in vitro. The cells
were cultured for 24 hours and then analyzed by FACS. (C) Apoptotic rates of progenitor and stem cells in vivo. Progenitor and stem cells were
labeled with 7AAD and Annexin V, and analyzed by FACS (n=5). **: p,0.01. (D) Cell cycle analysis of progenitor and stem cells in vivo. The cells were
stained with Hoechst Blue, and the cells in the S+G2M phase were analyzed by FACS (n=5). **: p,0.01.
doi:10.1371/journal.pone.0038614.g001
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WT donor cells. We found that the Alox5 deficiency caused a
significant increase in the percentage of bone marrow GFP+LSK-
cells (Fig. 4B). Consistent with this finding, CML mice treated with
Zileuton, which reduces survival of CML LSCs by inhibiting the
function of 5-lipoxygenase (the Alox5 gene product) [17], had a
marked increase in bone marrow GFP
+LSK
2 cells (Fig. 4C). The
increase in LSK
2 cells explains the depletion of LSCs in CML
mice treated with Zileuton [17], which could be a general
mechanism utilized by chemical compounds that suppress LSCs.
To strengthen this idea, we examined whether LSK
2 cells are also
increased in CML mice treated with a HSP90 inhibitor, IPI-504,
which has been shown to inhibit LSCs in CML mice [18]. In this
experiment, we used BCR-ABL-T315I to induce CML in mice,
because we previously showed that compared to wild type BCR-
ABL, CML cells harboring BCR-ABL-T315I in mice were more
dependant on HSP90 for stability and therefore BCR-ABL-T315I
protein was more sensitive to HSP90 inhibition for degradation
[9], providing a more sensitive assay for testing the transition of
LSCs to LSK- cells. We found that IPI-504 treatment caused a
marked increase in LSK
2 cells compared with the CML mice
treated with a placebo (Fig. 4D). These results demonstrate that
the transition from LSK cells or LSCs to apoptotic LSK
2 cells
provides a cellular pathway for regulating these two cell
populations.
Icsbp and Lyn regulate the transition of LSK to LSK
2 cells
To study the underlying mechanisms for the transition between
LSK and LSK
2 cells, we decided to focus on the interferon
consensus sequence binding protein (Icsbp) gene, because mice
lacking Icsbp (Icsbp
2/2) develops CML-like disease [19]. Our DNA
microarray study showed that Icsbp was downregulated by BCR-
ABL in LSCs and this downregulation was partially restored in
Alox5
2/2 LSCs (Fig. S3). This result was confirmed by RT-PCR
(Fig. S4). Expression of Icsbp is also down-regulated in CML
patients [20]. Furthermore, we found that the percentage of LSK
2
cells in bone marrow of Icsbp
2/2 mice (8 weeks old) was
dramatically lower than that in WT mice (Fig. 5A), suggesting
that the normal function of Icsbp is to promote the transition of
LSK cells to LSK
2 cells. A plausible explanation for the
development of CML-like disease in Icsbp
2/2 mice is that when
Icsbp is removed, LSK cells could not undergo the transition to
apoptotic LSK
2 cells, and the LSK population could only be
regulated through differentiating to become more mature myeloid
cells, eventually leading to the development of CML-like disease,
as observed in Icsbp
2/2 mice [19]. Consistent with this idea, the
percentage and total number of LSK
2 cells in bone marrow of old
Icsbp
2/2 mice (24 weeks old) was much lower than that in old WT
mice (Fig. S5). The function of Icsbp in controlling the transition of
LSK to LSK
2 cells was also demonstrated in BXH2 mice, in
which the function of Icsbp is impaired by a R294C mutation,
leading to an eventual development of CML-like disease [21]. We
observed that similar to Icsbp
2/2 mice, BXH2 mice had a lower
percentage of LSK
2 cells than did WT mice (Fig. 5B). We then
examined the percentages of dividing and apoptotic cells in Icsbp
-/-
mice (Fig. 5C, D), and found that LSK
2 cells in Icsbp
2/2 mice
were relatively apoptotic and quiescent, similar to the LSK
2 cells
in WT mice (Fig. 2B, C). These results indicate that Icsbp does not
regulate cell cycle and apoptosis of LSK
2 cells but controls the
transition of LSK to LSK
- cells.
Our finding of the role of Icsbp in the regulation of LSK
transition prompted us to further investigate this Icsbp genetic
Figure 2. Irradiation and 5-FU treatment promote cellular transition of LSK to LSK
2 cells. (A) Lethal irradiation causes an increase in the
percentage of apoptotic LSK
2 cells. Mice were treated by two split doses of 550-cGy gamma irradiation (separated by 3 hours), and the apoptotic
cells (7AAD
+Annexin V
+) in the LSK
2 population were analyzed by FACS at different time points (n=4). **: p,0.01. (B) Total number and percentages
of LSK and LSK
2 cells in bone marrow of lethally irradiated WT mice were determined at different time points (n=4). *: p,0.05; **: p,0.01. (C) Total
number and percentages of LSK and LSK
2 in bone marrow of 5-FU treated WT mice at different time points. The mice were treated with 5-FU
(200 mg/kg) by intravenous injection, and the percentages of LSK and LSK
2 cells were monitored at different time points (n=4). *: p,0.05; **:
p,0.01. (D) The apoptotic rate of LSK
2 cells in 5-FU treated mice. WT mice were treated with 5-FU, and apoptotic rate of LSK
2 cells were monitored
at different time points (n=4). *: p,0.05; **: p,0.01.
doi:10.1371/journal.pone.0038614.g002
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hematopoiesis. Lyn-deficient mice display a collection of hemato-
poietic defects, including autoimmune disease as a result of
autoantibody production, and perturbations in myelopoiesis that
ultimately lead to splenomegaly and myeloid neoplasia, similar to
CML-like disease observed in Icsbp
2/2 mice [22]. Induction of
Icsbp expression in the Icsbp
2/2 myeloid progenitor cells leads to
an upregulation of Lyn expression [23]. Therefore, we tested
whether Lyn is involved in the regulation of the LSK population by
Icsbp through controlling the transition of LSK to LSK
2 cells. We
first compared the mRNA levels of Lyn in bone marrow between
WT and Icsbp
2/2 mice by RT-PCR, and found that Lyn was
downregulated in Icsbp
2/2 bone marrow cells (Fig. 5E), suggesting
that Lyn is downstream of Icsbp. We next determined whether the
LSK
2 cell population is reduced in Lyn
2/2 mice. Consistent with
Icsbp
2/2 mice (Fig. 5A), the percentage of LSK
2 cells in bone
marrow of Lyn
2/2 mice was significantly reduced (Fig. 5F),
demonstrating that Lyn is also involved in the transition of LSK to
LSK
2 cells. Furthermore, we tested whether expression of Lyn in
bone marrow cells from Lyn
2/2 mice restores the cellular
transition. We transduced Lyn
2/2 bone marrow cells with
MSCV-GFP or MSCV-Lyn-GFP retrovirus, followed by transplan-
tation of the transduced cells into recipient mice. The percentage
of LSK
2 cells in recipients of MSCV-Lyn-GFP transduced Lyn
2/2
bone marrow cells was about two-fold higher than that in
recipients of MSCV-GFP transduced Lyn
2/2 bone marrow cells
(6.59% vs. 3.79%) (Fig. 5G), supporting the role of Lyn as a
downstream regulatory gene of Icsbp in maintaining the transition
of LSK to LSK
2 cells.
The transition of LSCs to the LSK
2 cell population is
blocked in CML
Because LSK
2 cells in bone marrow of WT and Icsbp
2/2 mice
are more apoptotic than LSK cells (Fig. 1C and Fig. 5D), we
thought that this cellular pathway controlled by Icsbp might also
play a role in regulating LSCs in CML mice. To test this idea, we
first examined whether BCR-ABL-expressing LSK
2 cells contain
more apoptotic cells than LSCs in bone marrow of CML mice,
and found that apoptotic cells in the GFP
+LSK
2 cell population
were two-fold higher than those in the GFP
+LSK cell population
(Fig. 6A). We wondered whether the effect of imatinib treatment is
also associated with the LSK
2 cell population, and found that
20 days after CML induction, the percentage of LSK
2 population
was about 3.93% in placebo treated CML mice and 8.62% in
imatinib treated CML mice (Fig. 6B), suggesting that the
therapeutic effect of imatinib is associated with increased cellular
transition of LSK cells. Because the BCR-ABL kinase inhibitor
imatinib has an initial therapeutic effect but does not eliminate
LSCs in CML mice [7,17], we reasoned that the failure of imatinib
to cure CML mice should be associated with an inability of
imatinib to cause an increase in the transition of LSCs to LSK
2
cells in CML mice treated for a long period of time. We observed
Figure 3. An increase in LSK
2CD150
2 cells reflects apoptosis of HSCs. (A) The LSK
2 cell population is basically CD150-negative. LSK
+
(Lin
2Sca1
+c-Kit
+) cells and LSK
2 (Lin
2Sca1
+c-Kit
2) cells from bone marrow of B6 mice were stained with CD150, and analyzed by FACS. (B) High
apoptotic rates in bone marrow LSK
2CD150
2 cells. LSK
+ and LSK
2 cells from bone marrow of B6 mice were stained with CD150, further labeled with
7AAD and Annexin V, and analyzed by FACS. Apoptotic rate for each cell population was indicated. (C) An increase in LSK
2CD150
2 cells reflects
apoptosis of HSCs. B6 mice were treated with irradiation or 5-FU for different days as indicated. LSK
+ and LSK
2 cells from bone marrow of B6 mice
were stained with CD150, were further labeled with 7AAD and Annexin V, and analyzed by FACS.
doi:10.1371/journal.pone.0038614.g003
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BCR-ABL-expressing LSK
2 cells. (A) BCR-ABL
+LSK cells give rise to LSK
2 cells in CML mice. 1610
6 bone marrow cells (containing BCR-ABL
+LSK
Apoptosis of Normal and Leukemic Stem Cells
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2 cells in bone marrow of imatinib-
treated CML mice increased transiently, but eventually decreased
to a level similar to that in untreated CML mice (Fig. 6C). This
result suggests that LSCs somehow find a way to overcome
imatinib-mediated inhibition of the transition of LSCs to apoptotic
LSK
2 cells.
The development of CML-like disease in Icsbp
2/2 mice
prompted us to examine whether Icsbp regulates the transition of
LSK cells to more apoptotic LSK
2 cells during normal
hematopoiesis. Because irradiation or 5-FU treatment causes a
decrease in LSK cells and an increase in the apoptotic LSK
2 cells
(Fig. 2B, C), we detected Icsbp expression in bone marrow cells by
real-time PCR under both conditions. We found that Icsbp
expression levels were increased after irradiation (Fig. 6D) and 5-
FU treatment (Fig. 6E), which were associated with the increase of
LSK
2 cells (Fig. 2B, C).
Discussion
During normal hematopoiesis, HSCs progressively give rise to
different progenitor cells, which in turn generate various mature
cell lineages [24,25,26]. This process is precisely controlled to
maintain each cell population. Homeostasis between the quiescent
and activated states of stem cells is essential to balance stem cell
maintenance with ongoing tissue regeneration [23]. In addition,
HSCs and their lineage choices are tightly regulated by Pten to
prevent AML initiation from HSCs [27,28]. In CML develop-
ment, normal control of hematopoiesis is largely disturbed at the
level of HSCs [29,30,31,32]. A complete study of the underlying
mechanisms is critical for understanding how HSCs and LSCs
survive and self-renew. In this study, we found that the LSK
2
population derived from HSC-containing LSK cells does not have
stem cell functions but is capable of regulating the survival of the
LSK population by providing a cellular path for irreversible
transition of LSK to highly apoptotic LSK
2 cells. Activation of
this apoptotic cellular pathway is normally maintained by
expression of the Icsbp, Lyn and likely other related genes, and
during myeloid transformation such as in CML, this pathway is
shut down due to Icsbp downregulation. It is reasonable to
speculate that when the number of LSK cells needs to be reduced
to maintain the LSK population, the transition of LSK to
apoptotic LSK
2 cells would help to remove overly produced LSK
cells. If this cellular pathway were blocked, LSK cells would be
forced to differentiate, which would favor the development of
myeloproliferative disease (Fig. 6F). This idea is supported by our
observation that BCR-ABL causes an increase in the LSC
population and that the defect in CML induction by BCR-ABL
in the absence of Alox5 is associated with increases in Icsbp
expression and the percentage of BCR-ABL-expressing apoptotic
LSK
2 cells (Fig. 6F). In CML patients, Icsbp has been found to be
downregulated [20]. Overexpression of Icsbp causes a delayed
development of BCR-ABL induced CML in mice [33]. The
maintenance of an active cellular pathway for apoptosis of LSCs
by the Icsbp pathway provides an alternative explanation for the
tumor suppressor role of Icsbp in CML development.
Comparing the LSK
2 cells derived from normal HSCs and
BCR-ABL-expressing LSK cells in CML, we did not observe any
difference in the apoptotic rates. Thus, we believe that both
normal HSCs and BCR-ABL
+ LSK cells can similarly give rise to
LSK
2 cells. Because LSK
2 cells can only arise from HSCs or
BCR-ABL-expressing LSKs and have a much higher apoptotic
rate, the transition to LSK
2 cells would provide a regulatory
mechanism for the survival of HSCs and BCR-ABL-expressing
LSKs, which would ultimately affect normal hematopoiesis and
leukemogenesis. On the other hand, because imatinib does not
have a significant effect on CML stem cells, we would not expect
that imatinib stimulates the transition of BCR-ABL-expressing
LSK cells to LSK
2 cells.
The molecular mechanism for maintaining and regulating the
survival of the LSK population is poorly understood, and available
evidence shows that it is a genetically-regulated process involving
specific genes expressed in HSCs and bone marrow niche
[10,11,12]. In this study, we provide evidence showing that the
transition of HSC-containing LSK cells to apoptotic LSK
2 cells is
regulated by Icsbp and Lyn. It is reasonable to think that in myeloid
proliferative diseases, expression of Icsbp and Lyn are inhibited,
leading to a blockade of the transition of malignant LSK to LSK
2
cells. This transition blockade would cause an increase in the
malignant LSK. In support of this idea, we have shown that in
CML, the BCR-ABL oncogene is expressed in LSK cells and
causes an increase in this cell population [9,13], and in this study
we show that the transition blockade occurs in CML. It is likely
that LSK cells communicate with LSK
2 cells to mutually regulate,
and Icsbp and Lyn are somehow involved. Although the underlying
mechanisms are totally unknown, it is reasonable to think that cell-
cell interaction and secreted cytokines could play roles in the
regulation of this cellular transition. Further studies will help to
answer these questions. Besides the Icsbp/Lyn pathway, it is highly
possible that the transition of LSK to apoptotic LSK
2 cells may
also be regulated by other unknown mechanisms, and complete
understanding of the molecular basis of these pathways will help to
develop new strategies for targeting stem cells in the treatment of
human diseases related to HSCs and LSCs.
Methods
Mice
C57BL/6J (B6) (CD45.2 positive), congenic B6 mice expressing
CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ), B6.129S2-Alox5
tm1Fun/J
(Alox5
2/2), and B6.129S4-Lyn
tm1Sor/J (Lyn
2/2) mice were obtained
from The Jackson Laboratory. Icsbp
-/- mice were kindly provided
by Dr. Herbert C. Morse (Laboratory of Immunopathology,
NIAID, NIH). Mice were maintained in a temperature and
humidity controlled environment and given unrestricted access to
6% chow diet and acidified water. All animal studies were
approved by Institutional Animal Care and Use Committee.
cells) from primary CML mice were transplanted into each secondary recipient mouse. 15 days later, bone marrow cells were analyzed by FACS for
the presence of BCR-ABL
+LSK and LSK
2 cells. (B) Alox5 deletion enhanced the transition of LSCs (GFP
+LSK) to GFP
+ LSK
2 cells. At day 20 after
induction of CML, the percentage of LSCs and GFP
+ LSK
2 cells in bone marrow of recipients of BCR-ABL transduced WT donor marrow cells were
determined (top panel), and the percentage of GFP
+LSK
2 cells was lower than that of LSCs. In recipients of BCR-ABL transduced Alox5
2/2 donor
marrow cells, the percentage of GFP
+ LSK
2 cells became higher than that of LSCs (middle panel). At day 90, the percentage of GFP
+LSK
2 cells reached
as high as 50% (bottom panel) (n=4 for each group). **: p,0.01. (C) Inhibition of Alox5 function by Zileuton enhanced the transition of LSCs to BCR-
ABL expressing Lin
2Sca1
+c-Kit
2 cells. CML mice were treated with Zileuton (300 mg/kg body weight, twice a day) for 90 days and the percentages of
LSCs and GFP
+LSK
2 were monitored by FACS (n=4 for each group). **: p,0.01. (D) The percentages of LSCs and BCR-ABL-T315I expressing
Lin
2Sca1
+c-Kit
2 cells were measured by FACS after IPI-504 treatment. Bone marrow cells from CML mice were cultured under a stem cell culture
condition in the presence of IPI-504 (100 nM) for 6 days, and the percentages of LSCs and GFP
+LSK
2 were determined by FACS. *: p,0.05.
doi:10.1371/journal.pone.0038614.g004
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The retroviral constructs MSCV-GFP, MSCV-BCR-ABL-GFP
and MSCV-Lyn-GFP were used to make retroviral stocks by
transient transfection of 293T cells using the kat system as
previously described [34]. Six to ten week-old wild type and Lyn
2/
2 mice were used for leukemogenesis and Lyn overexpression
experiments. Induction of CML in mice was done as described
previously
11. Briefly, to induce CML, bone marrow cells from 5-
FU (200 mg/kg) donor mice were transduced twice with BCR-
ABL retrovirus by cosedimentation in the presence of IL-3, IL-6,
Figure 5. The Icsbp-Lyn pathway controls the transition of LSK to LSK
2 cells. (A) The percentages and numbers of LSK, LSK
2 and
Lin
2Sca1
2c-Kit
+ were compared between WT and Icsbp
2/2 mice (n=4 for each group). *: p,0.05; **: p,0.01. (B) The percentages of LSK, LSK
2 and
Lin
2Sca1
2c-Kit
+ were compared between WT and BXH2 mice. (C) Cell cycle analysis of progenitor and stem cells in Icsbp
2/2 mice. Bone marrow cells
were stained with Hoechst blue, and DNA contents, represented by the percentages of progenitor and stem cells in the S+G2M phase of the cell
cycle, were examined by FACS (n=4). **: p,0.01. (D) Apoptotic rates of progenitor and stem cells in Icsbp
2/2 mice. The cells were labeled with 7AAD
and Annexin V, and the percentages of progenitor and stem cells were determined by FACS (n=4). **: p,0.01. (E) Lyn expression in bone marrow
cells was compared between WT and Icsbp
2/2 mice. Bone marrow cells were collected from WT and Icsbp
2/2 mice, respectively, and Lyn expression
was detected by real-time PCR (n=3). *: p,0.05. (F) The percentages of LSK and LSK
2 were compared between WT and Lyn
2/2 mice. Lyn deletion
caused an increase in the percentage of LSK and decrease in the percentage of LSK
2 cells. (G) Overexpression of Lyn caused an increase in the LSK
2
population. Lyn
2/2 bone marrow cells were transduced with MSCV-GFP or MSCV-Lyn-GFP retrovirus, followed by transplantation of the transduced
cells into lethally irradiated WT recipient mice. At day 60 after the transplantation, the percentages of LSK and LSK
2 cells were determined by FACS.
doi:10.1371/journal.pone.0038614.g005
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gamma irradiation. A dose of 0.5610
6 (CML) cells was
transplanted into recipient mice via tail vein injection.
Flow cytometry
Hematopoietic cells were collected from peripheral blood and
bone marrow of the wild type, Icsbp
2/2, Lyn
2/2, and CML mice,
and red blood cells were lysed with NH4Cl red blood cell lysis
Figure 6. Long-term treatment of CML mice with imatinib fails to promote the transition of LSCs to BCR-ABL expressing LSK
2 cells.
(A) Apoptotic rates between LSCs and BCR-ABL expressing LSK
2 cells in CML mice were compared. At day 14 after induction of CML, apoptotic rate
in GFP
+LSK
2 was slightly higher than that of LSCs. (B) The percentage of GFP
+LSK
2 cells was increased after imatinib treatment for 12 days,
beginning at day 8 after induction of CML (100 mg/kg). (C) The percentages of LSCs and GFP
+LSK
2 cells in bone marrow of CML mice were compared
after imatinib treatment for 55 days. *: p,0.05; **: p,0.01. (D) Icsbp expression was increased in bone marrow cells of mice treated with lethal
irradiation. Bone marrow cells were collected from lethally irradiated mice at day 0, 2 and 4 after irradiation. Total RNA was extracted and Icsbp
expression was determined by real-time PCR. *: p,0.05. (E) Icsbp expression in bone marrow cells was determined in 5-FU treated mice. Bone marrow
cells were collected from 5-FU treated mice at day 0, 2, 4 and 6 after the treatment, and total RNA was extracted and Icsbp expression was determined
by real-time PCR. *: p,0.05; **: p,0.01. (F) Proposed molecular model for the control of the transition of LSK/LSCs and LSK
2 cells. The balance
between LSK and LSK
2 cells is controlled by the Icsbp/Lyn pathway in normal hematopoiesis and by Alox5 in BCR-ABL induced CML.
doi:10.1371/journal.pone.0038614.g006
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B-220 for B cells, Gr-1 for neutrophils, Lin
-Sca-1
+c-Kit
+ for
hematopoietic stem cells, Hoechst blue for DNA, and 7AAD/
Annexin V for apoptosis analysis. Lineage cocktail includes anti-
CD5 (rat IgG2a), anti-CD11b (rat IgG2a), anti-CD45R (B220) (rat
IgG2a), anti-7-4 (rat IgG2a), anti-Gr-1 (Ly-6G/C, rat IgG2a), and
anti-Ter-119 (rat IgG2b).
In vitro culture of leukemia stem cells
Bone marrow cells isolated from CML mice were culture in
vitro in the presence of stemspan SFEM, SCF, IGF-2, TPO,
heparin and a-FGF as described previously [9].
Drug treatment
Imatinib was dissolved in water directly at a concentration of
10 mg/ml, and administered orally by gavage in a volume less
than 0.5 ml (100 mg/kg body weight, twice a day), beginning at
day 8 after induction of CML and continuing until the morbidity
or death of leukemic mice. Zileuton (Critical Therapeutics) was
dissolved in water. The drugs were given orally by gavage
(300 mg/kg, twice a day), beginning at 8 days after induction of
CML, and continuing until the morbidity or death of the mice
with leukemia. IPI-504 was dissolved in a solution containing
50 mM citrate, 50 mM ascorbate, 2.44 mM EDTA, pH 3.3.
RNA extraction and real-time PCR
Total mRNA was isolated from HSCs or LSCs sorted by FACS,
and cDNA was synthesized using the Ovation-Pico cDNA
synthesis method. Real-time PCR (RT-PCR) was carried out to
detect expression of b-actin, Icsbp and Lyn with the primers for b-
actin (forward: GGGGTGTTGAAGGTCTCAAA; reverse:
ACTGGGACGACATGGAGAAG), Icsbp (forward: CA-
GATCCTCCCTGACTGGTG; reverse: CATCCGGCCCA-
TACA ACTTA), and Lyn (forward: ACCCTTATGATGG-
CATCCAC; reverse: GAAAGCTCCTGCACTGT TGC).
Data analysis and statistical methods
Statistical analyses were performed by t test or GraphPad Prism
v5.01 software for Windows (GraphPad Software, San Diego, CA
USA).
Supporting Information
Figure S1 LSK
2 cells cannot be produced from Lin
2cK-
it
+Sca1
2 (LS
2K) cells. CD45.1
+LS
2K cells were sorted from
bone marrow of mice by FACS and transplanted into CD45.2
recipient mice (1610
6 per mouse). CD45.1 cells in peripheral
blood (A) or bone marrow (B) of recipient mice were monitored
with time.
(PDF)
Figure S2 Induction of CML in secondary recipient
mice. (A) Bone marrow cells were transduced with BCR-ABL-
GFP or empty vector (as a control) to induce primary CML. Bone
marrow cells from primary CML mice were transplanted into
secondary recipient mice (1610
6 cells per mouse). The mice
developed CML, as shown by FACS analysis of peripheral blood
(A) and died (B).
(PDF)
Figure S3 DNA microarray analysis shows downregu-
lation of Icsbp expression by BCR-ABL in LSCs and
partial restoration of Icsbp expression in the absence of
Alox5.
(PDF)
Figure S4 Real-time PCR analysis shows downregula-
tion of Icsbp expression by BCR-ABL in LSCs and
restoration of Icsbp expression in the absence of Alox5.
*: p,0.05.
(PDF)
Figure S5 Loss of Icsbp causes a decrease of LSK
2 cells
in aged mice. Bone marrow cells from aged WT and Icsbp2/2
mice (24 weeks) were collected and the percentages and numbers
of LSK and LSK
2 cells in bone marrow were measured by FACS.
**: p,0.01.
(PDF)
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